Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Brady Stein
Treatment Options for Patients With Chronic Myeloid Leukemia Who Are Resistant to or Unable to Tolerate Imatinib
Clinical Therapeutics
Pharmacology
Related publications
Long-Term Efficacy and Safety of Dasatinib in Patients With Chronic Myeloid Leukemia in Accelerated Phase Who Are Resistant to or Intolerant of Imatinib
Blood Cancer Journal
Oncology
Hematology
Long-Term Safety and Efficacy of Dasatinib in the Treatment of Chronic-Phase Chronic Myeloid Leukemia Patients Resistant or Intolerant to Imatinib
Blood and Lymphatic Cancer: Targets and Therapy
Polycomb Genes Are Associated With Response to Imatinib in Chronic Myeloid Leukemia
Epigenomics
Cancer Research
Genetics
Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia
Haematologica
Hematology
Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
CT-guided Percutaneous Irreversible Electroporation for Patients With Locally Advanced Pancreatic Cancer Who Are Unable to Tolerate Periodic Standard Chemotherapy
HPB
Hepatology
Gastroenterology
Prognostic Value of Tumor Clones Early Reducation in Patients With Chronic Myeloid Leukemia on Nilotinib Treatment Who Failed Imatinib
Hematology & blood transfusion: interdepartamental collection
Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients
